ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1410	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	Surgical Adjuvant Breast 0.47836 Obstet Gynecol 0.483376 World Cancer Research 0.452806 endometrial carcinoma 0.52954 Engl J Med 0.456388 American Cancer Society 0.497798 Br J Cancer 0.455416 case-control study 0.441437 Int J Cancer 0.478131 early-stage breast cancer 0.461817 intentional weight loss 0.529248 breast cancer treatment 0.473891 breast cancer patients 0.472714 body mass index 0.470175 endometrial cases 0.529694 Cancer Causes Control 0.452081 Natl Cancer Inst 0.529481 lower endometrial cancer 0.563354 postmenopausal endometrial cancer 0.554715 modifiable risk factor 0.44186 endometrial cancer 0.948645 invasive breast cancer 0.472622 Cancer Treat Rep 0.454232 et al. 0.498732	early breast cancer 0.472532 tamoxifen-treated breast cancer 0.462067 nonpolyposis colorectal cancer 0.457467 endometrial cancer cases 0.601622 polycystic ovarian syndrome 0.445837 Cancer Epidemiol Biomarkers 0.47249 endometrial cancer risk 0.82277 Cancer Facts 0.44862 PUBMED Abstract 0.515106 Nutr Cancer 0.444116 widespread endometrial cancer 0.555715 Epidemiol Biomarkers Prev 0.442397 endometrial cancer incidence 0.612962 Breast Cancer Prevention 0.475561 African American women 0.440785 invasive gynecologic cancer 0.464853 postmenopausal women 0.497969 Abstract 0.52778 breast cancer 0.526041 adjuvant tamoxifen 0.441172 physical activity 0.445711 Breast Cancer Study 0.467445 breast cancer incidence 0.479289 National Surgical Adjuvant 0.475167	CLICK HERE
1417	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary.	randomized placebo-controlled trial 0.595383 gastric adenomatous polyps 0.679902 experimental animal models 0.575229 infected family members 0.578256 antioxidant dietary supplements 0.574787 H. pylori 0.663672 annual incidence rates 0.588818 secondary prevention measures 0.572741 age-adjusted incidence rate 0.59463 statistically significant reduction 0.578799 combined antioxidant groups 0.572868 H. pylori infection 0.650947 high H. pylori 0.585004 family members 0.581961 gastric cancer mortality 0.686327 endoscopic resection techniques 0.578064 placebo group 0.585452 chemoprevention trial 0.590009 H. pylori-infected family 0.583244 Li Fraumeni syndrome 0.58425 intestinal metaplasia 0.628781 advanced premalignant lesions 0.570945 protective effects 0.575049 low selenium content 0.586292	statistically significant effect 0.623477 Beta Carotene trial 0.587524 United States 0.702911 gastric cancer incidence. 0.664051 precancerous gastric lesions. 0.647932 5-year survival rate 0.635247 gastric cancer cases 0.674324 gastric cancers 0.625749 gastrointestinal cancers 0.575893 H. pylori-infected people 0.581367 overall 5-year survival 0.57409 beta carotene 0.671292 small randomized trial 0.598139 gastric cancer 0.97116 gastric adenocarcinoma. 0.625249 eradication therapy 0.572355 Chinese medical journal 0.572216 vitamin supplementation 0.570623 statistically significant regression 0.573687 chronic atrophic gastritis 0.586209 gastric cancer. 0.610162 close family members. 0.576811 family history 0.58364 steady incidence rates 0.587586	CLICK HERE
1501	National Cancer Institute	Html	en	Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.	nodular sclerosis hodgkin 0.365708 refractory pediatric Hodgkin 0.351319 refractory Hodgkin 0.416042 early Hodgkin lymphoma 0.394054 Hodgkin lymphoma cases 0.403293 Hodgkin disease-added value 0.362383 early-stage hodgkin lymphoma 0.391985 lymphocyte-predominant hodgkin 0.393688 Radiat Oncol Biol 0.45608 risk Hodgkin lymphoma 0.399452 favorable-risk Hodgkin lymphoma 0.388818 Hodgkin lymphoma histology 0.402552 pediatric hodgkin lymphoma 0.479624 German-Austrian Pediatric Hodgkin 0.419443 classic Hodgkin lymphoma 0.417403 pediatric Hodgkin disease 0.379402 high-risk Hodgkin lymphoma 0.432447 Hodgkin Study Group 0.371284 sclerosis Hodgkin lymphoma 0.410888 newly diagnosed Hodgkin 0.350548 Hodgkin lymphoma treatment 0.38529 childhood hodgkin lymphoma 0.384013 familial classical Hodgkin 0.365775 lymphocyte-predominant Hodgkin lymphoma-experience 0.349402 childhood hodgkin 0.486255	cancer survivor study 0.348591 et al. 0.539517 lymphocyte-rich classical Hodgkin 0.347809 pediatric hodgkin 0.578037 intermediate-risk hodgkin lymphoma 0.423631 advanced Hodgkin lymphoma 0.416897 refractory Hodgkin lymphoma 0.395506 PUBMED Abstract 0.412711 unfavorable pediatric Hodgkin 0.351719 Hodgkin lymphoma subtype 0.402744 Lymphocyte-predominant Hodgkin lymphoma 0.388987 advanced-stage Hodgkin 0.357413 lymphocyte predominant Hodgkin 0.374597 Abstract 0.561102 Clin Oncol 0.905331 Hodgkin Lymphoma Group 0.412086 classical Hodgkin lymphoma 0.427321 Oncol Biol Phys 0.463188 Hodgkin disease 0.410937 childhood cancer survivor 0.348315 unfavorable childhood Hodgkin 0.356068 hodgkin lymphoma 0.82441 recurrent Hodgkin lymphoma 0.392381 predominant Hodgkin lymphoma 0.394303	CLICK HERE
1513	National Cancer Institute	Html	en	Pancreatic Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic cancer.	pancreatic carcinoma E6201 0.398831 unresectable pancreatic carcinoma 0.359985 pancreatic malignancy 0.311753 Engl J Med 0.337007 Ann Surg 0.317423 German CONKO-study group 0.318318 phase iii trial 0.413157 pancreatic tumors 0.328586 der Schelling GP 0.325496 randomized phase 0.350612 advanced pancreatic adenocarcinoma 0.470438 randomized trial 0.376847 patients 0.470655 investigational new drug 0.321651 Cooperative Oncology Group 0.454021 van der Schelling 0.325555 Moore MJ 0.343635 fixed-dose rate infusion 0.313379 pancreatic carcinoma 0.542646 Ann Oncol 0.304631 et al. 0.690156 Best supportive care 0.315629 study 0.356854 Expandable metal stents 0.329142	phase ii trial 0.320548 Hammel et al. 0.336299 Oncology Group study 0.328761 Clinical Trials Group 0.319844 gemcitabine-based induction chemotherapy 0.328647 National Cancer Institute 0.337583 den Bosch RP 0.325608 advanced unresectable pancreatic 0.366836 metastatic pancreatic cancer 0.353118 advanced pancreatic cancer 0.926655 advanced pancreatic carcinoma 0.404683 unresectable periampullary adenocarcinoma 0.332936 first-line therapy 0.306838 van den Bosch 0.324595 refractory pancreatic cancer 0.407704 advanced pancreas cancer 0.35576 Abstract 0.559395 Clin Oncol 0.91428 unresectable pancreatic cancer 0.410252 Canada Clinical Trials 0.318756 Eastern Cooperative Oncology 0.46104 drug treatment program 0.320206 gemcitabine 0.380059 active chemotherapy regimens 0.332336	CLICK HERE
1933	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de cáncer de seno (mama) en el embarazo.	estadio lllC 0.545921 procedimientos quizás 0.519027 estadio iv 0.622294 siguientes aspectos 0.528664 secciones llamadas lóbulos 0.542754 estadio lllB 0.547235 estadio lllA 0.548629 estadios ia 0.51696 ganglio linfático centinela 0.983407 Oncotype DX 0.522717 rayos x 0.518956 estadio ib 0.594193 prueba ayuda 0.551927 estadio ia 0.593122 pezón afección 0.529911 enlace drugs approved 0.522117 mama.ampliar cirugía 0.515861 causó hinchazón 0.517244 National Cancer Institute 0.51629 cuántos genes 0.520169	siguientes riesgos 0.513473 realidad células 0.541214 Instituto Nacional 0.528985 cuáles lesiones 0.51826 estadio iiia 0.547361 PDQ Tratamiento 0.523188 estadio iiic 0.745067 cáncer.ampliar mamografía 0.525478 estadio iia 0.550898 estadio llB 0.548944 estadio llA 0.550289 cuánta proteína 0.522295 siguientes casos 0.520535 Physician Data Query 0.558856 carcinoma lobulillar 0.602006 siguientes partes 0.548502 Breast Cancer 0.511799 mamas.ampliar carcinoma lobulillar 0.536157 siguientes pruebas 0.564002 vasos sanguíneos 0.630183	CLICK HERE
1989	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer.	etapa final 0.974283 posibles efectos tardíos 0.445113 células madre 0.448459 adultos jóvenes 0.631616 personas jóvenes 0.478657 posibles tratamientos 0.424654 siguientes aspectos 0.421705 cáncer causa estrés 0.501532 apoyo social escaso 0.437899 siguientes tipos 0.415041 largo plazo 0.418906 efectos tardíos 0.530812 familia reaccionarán 0.418853 National Cancer Institute 0.415958 siguientes riesgos 0.411551	siguientes maneras 0.446878 Instituto Nacional 0.427962 síntomasEl trastorno 0.423462 Cuidado paliativo 0.412419 distintos miembros 0.413316 tratamiento ayuda 0.457106 suicidioUn número 0.419685 siguientes efectos 0.419968 posibles efectos 0.465562 Physician Data Query 0.458553 sistema nervioso central 0.433857 mayores probabilidades 0.421125 Estados Unidos 0.416849 mejores tratamientos 0.417691	CLICK HERE
3670	National Cancer Institute	Html	es	Estudio TAILORx indica que mujeres con riesgo bajo de recurrencia de cáncer de seno pueden abstenerse de quimioterapia	Resumen de resultados del estudio TAILORx indica que mujeres con cáncer de seno receptor de hormonas en estadio inicial tienen un riesgo bajo de recurrencia según una prueba de expresión de 21 genes.	Assigning Individualized Options 0.731016 NIC-Clinical Trials Group 0.677172 Therapy Evaluation Program 0.674291 quimioterapia adyuvante mejora 0.979078 doctor joseph sparano 0.667749 doctora jo anne 0.660047 llamada puntuación 0.615517 Estados Unidos 0.857653 NRG Oncology 0.56481	excelentes resultados 0.548811 cuáles mujeres 0.873744 Oncotype DX® 0.57646 invasivo enfermedad 0.55814 New England Journal 0.693093 Clinical Oncology 0.572538 Nueva Zelanda 0.530968 estudio tailorx 0.733998	CLICK HERE
16256	National Cancer Institute	Html	en	Áreas de investigación	Sostener un progreso contra el cáncer requiere que se avance a través del continuo de investigación. Entérese de lo extenso que es el trabajo del NCI y de los programas que apoya el instituto para hacer avanzar la investigación oncológica.	National Cancer Institute 0.966549		CLICK HERE
16838	National Cancer Institute	Html	en	University of Texas — Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology	The focus of the University of Texas MD Anderson Cancer Nanotechnology Training Center is presented here.	unique boot camp 0.665183 lab management skills 0.648892 Rice University 0.515834 M.D. 0.338543 Objectives 0.334693 MD Anderson 0.892403 preparation 0.332958 independent careers 0.500052 problem 0.335383 MD Anderson CNTC 0.66004 Ph.D. 0.338612 seminar experiences 0.507875 translational research 0.966631 academic labs 0.516268 hands-on coursework 0.547621 project management 0.489839 Konstantin Sokolov 0.587384 future leaders 0.517794 independent research project 0.702082 Texas 0.33468 cancer nanotechnology 0.891595 translational research projects 0.795763 training program 0.532137 multidisciplinary mentorship 0.538033 post-doctoral training 0.533942	trainees 0.545607 specific interests 0.517161 Rebecca 0.339233 research fellowship grant 0.692269 multidisciplinary field 0.50801 Ph.D 0.333304 cancer translational research 0.824834 Cancer Management 0.515303 gap 0.336671 Principal Investigator 0.540969 Didactic coursework 0.550767 completion 0.335106 Center 0.334629 MD Anderson Cancer 0.714625 NCI Nanotechnology Characterization 0.789772 program faculty mentors 0.704052 current opportunities 0.49661 federal resources 0.494134 new discoveries 0.52212 Sunil Krishnan 0.581597 deep understanding 0.497785 barriers 0.38628 introductory course 0.486248 Training Focus 0.539936	CLICK HERE
17278	National Cancer Institute	Html	es	Preparación para cuidar a un enfermo con cancer	Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Las personas que cuidan a pacientes deben estar al tanto de muchas cosas y planificar el cuidado de su ser querido.	dándoles oportunidad 0.826428 !No hables así¡ 0.973126 Nueva York 0.867641 principales formas 0.895606 Oxford University 0.86575	Lynna J 0.87542 busque consejo 0.895137 mejores tratamientos 0.878203 surgen preguntas 0.922072	CLICK HERE